Results 91 to 100 of about 58,013 (257)

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

Functional Divergence in the Affinity and Stability of Non-Canonical Cysteines and Non-Canonical Disulfide Bonds: Insights from a VHH and VNAR Study

International Journal of Molecular Sciences
Single-domain antibodies, including variable domains of the heavy chains of heavy chain-only antibodies (VHHs) from camelids and variable domains of immunoglobulin new antigen receptors (VNARs) from cartilaginous fish, show the therapeutic potential of ...
Mingce Xu, Zheng Zhao, Penghui Deng, Mengsi Sun, Cookson K. C. Chiu, Yujie Wu, Hao Wang, Yunchen Bi   +7 more
semanticscholar   +1 more source

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers

Frontiers in Immunology, 2022
Claudin 18.2 (CLDN18.2), a tight junction (TJ) family protein controlling molecule exchange between cells, is frequently over-expressed in gastric cancer, pancreatic adenocarcinomas and in a fraction of non–small cell lung cancer cases.
W. Zhong, Yimin Lu, Zhe Ma, Yinjun He, Yongfeng Ding, Gaofeng Yao, Zhenxing Zhou, Jiali Dong, Yongliang Fang, Wei-wei Jiang, Weilin Wang, Yanshan Huang   +11 more
semanticscholar   +1 more source

Relationship Between Hospital Volume and Outcomes of Minimally Invasive Esophagectomy for Esophageal Cancer: Analysis of the National Clinical Database in Japan

Annals of Gastroenterological Surgery, EarlyView.
According to multivariable analysis conducted using a hierarchical logistic regression model, using VHH as the reference group, the odds ratios for mortality by hospital volume category were as follows: VLH, 2.70 (p < 0.0001); LH, 1.72 (p = 0.052); MH, 1.70 (p = 0.034); and HH, 1.43 (p = 0.173).
Soji Ozawa, Hiraku Kumamaru, Yuko Kitagawa, Kazuo Koyanagi, Junya Oguma, Harushi Udagawa, Hiroaki Miyata, Yasushi Toh, Hisahiro Matsubara   +8 more
wiley   +1 more source

FXII contact activation is dependent on binding through two unique patches in its EGF-1 domain and can be prevented by (VHH) targeting.

Journal of Thrombosis and Haemostasis
BACKGROUND Factor XII (FXII) triggers contact activation by binding to foreign surfaces, with the EGF-1 domain being the primary binding site. Blocking FXII surface-binding might hold therapeutic value to prevent medical device-induced thrombosis ...
R. Frunt, H. El Otmani, Simone Smits, C. Clark, Coen Maas   +4 more
semanticscholar   +1 more source

Comparison of Receptor‐Mediated Endocytosis and Its Application to Enhance DNA Transfection by TFAMoplex

Advanced NanoBiomed Research, EarlyView.
We developed an assay to distinguish cellular binding from internalization. Compatible with microscopy and high‐throughput screening, the method identifies ligand‐mediated uptake. Applying top candidates to a protein‐based DNA carrier enhanced transfection efficiency, providing a rational strategy to improve non‐viral gene delivery systems.
David Scherer, Steffen Honrath, Jonas Kurmann, Alexander Klipp, Finn Brigger, Jean‐Christophe Leroux   +5 more
wiley   +1 more source

Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration

mAbs
The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously ...
Paul Tamburini, Dennis Vestergaard Pedersen, D. Devore, Josh Cone, Rekha Patel, T. Hunter, F. Sun, G. R. Andersen, J. Hunter   +8 more
semanticscholar   +1 more source

Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains [PDF]

Structure, 2013
The epidermal growth factor receptor (EGFR) is implicated in human cancers and is the target of several classes of therapeutic agents, including antibody-based drugs. Here, we describe X-ray crystal structures of the extracellular region of EGFR in complex with three inhibitory nanobodies, the variable domains of heavy chain only antibodies (VHH).
Schmitz, K.R., Bagchi, A., Roovers, R.C., van Bergen en Henegouwen, P.M.P., Ferguson, K.M.   +4 more
openaire   +3 more sources

Nanobody and Its Therapeutic Applications

Journal of Mazandaran University of Medical Sciences, 2018
Background and purpose: Monoclonal antibodies market has grown since approval of Muromonab-CD3 (trade name Orthoclone OKT3) in 1986 as immuno- suppressor.
Maryam Darvish
doaj  

A novel single-domain antibody multimer that potently neutralizes tetanus neurotoxin

Vaccine: X, 2021
Tetanus antitoxin, produced in animals, has been used for the prevention and treatment of tetanus for more than 100 years. The availability of antitoxins, ethical issues around production, and risks involved in the use of animal derived serum products ...
Hans de Smit, Bart Ackerschott, Robert Tierney, Paul Stickings, Michiel M. Harmsen   +4 more
doaj   +1 more source